ABVC Biopharma Inc - Asset Resilience Ratio
ABVC Biopharma Inc (ABVC) has an Asset Resilience Ratio of 0.32% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ABVC current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how ABVC Biopharma Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ABVC Biopharma Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down ABVC Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of ABVC Biopharma Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $62.42K | 0.32% |
| Total Liquid Assets | $62.42K | 0.32% |
Asset Resilience Insights
- Limited Liquidity: ABVC Biopharma Inc maintains only 0.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ABVC Biopharma Inc Industry Peers by Asset Resilience Ratio
Compare ABVC Biopharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for ABVC Biopharma Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for ABVC Biopharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.31% | $64.35K | $21.06 Million | -0.55pp |
| 2024-12-31 | 0.86% | $64.74K | $7.54 Million | -0.16pp |
| 2023-12-31 | 1.02% | $79.31K | $7.78 Million | +0.33pp |
| 2022-12-31 | 0.69% | $75.80K | $10.93 Million | -0.10pp |
| 2021-12-31 | 0.79% | $108.15K | $13.70 Million | -7.27pp |
| 2020-12-31 | 8.06% | $1.19 Million | $14.77 Million | -40.50pp |
| 2019-12-31 | 48.57% | $3.36 Million | $6.93 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $6.60 Million | -- |
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more